annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM
Novel Therapies and Approaches for Management of Gynecologic Cancers
Location: E Arie Crown Theater
CME credit: 1.5
Track(s): Gynecologic Cancer
Robert L. Coleman, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
Ronald J. Buckanovich, MD—Co-Chair
University of Michigan
9:45 AM Randomized, double-blind, placebo-controlled phase II study of AMG 386
combined with weekly paclitaxel in patients (pts) with recurrent ovarian
carcinoma. (Abstract #5000)
B. Y. Karlan, A. M. Oza, V. L. Hansen, G. E. Richardson, D. M. Provencher,
P. Ghatage, M. Tassoudji, D. E. Stepan, D. M. Weinreich, I. B. Vergote
Discussion
10:00 AM George Coukos, MD, PhD (Abstract #5000)
University of Pennsylvania, Perelman Center for Advanced Medicine
Anti-angiogenic Options in Ovarian Cancer
10:15 AM Efficacy and safety of farletuzumab, a humanized monoclonal antibody to
folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects:
Final data from a multicenter phase II study. (Abstract #5001)
A. J. White, R. L. Coleman, D. K. Armstrong, D. Glenn, A. Bicher, D. A. Richards,
A. Schneeweiss, L. J. Old, C. Schweizer, S. Weil
Discussion
10:30 AM Alan Hilary Calvert, MD (Abstract #5001)
Cancer Research Unit
Targeting the Folate Receptor in Ovarian Cancer
10:45 AM Final results of a phase II study of voreloxin in women with
platinum-resistant ovarian cancer. (Abstract #5002)
H. W. Hirte, W. P. McGuire III, R. P. Edwards, A. Husain, P. Hoskins, J. E. Michels,
U. Matulonis, C. Sexton, J. A. Fox, G. Michelson
Discussion
11:00 AM Hani Gabra, PhD, FRCP (Abstract #5002)
Imperial College, London
Mechanisms of Resistance in Ovarian Cancer
352